Colorectal cancer's molecular complexity keeps yielding unexpected drivers, and this finding reframes how non-coding RNA can act as a stabilizing shield for oncogenic protein machinery — a mechanism with direct implications for how tumors rewire metabolism without altering the genome itself. Understanding this axis could open a class of therapeutic targets currently outside the field's radar.
Researchers publishing in PNAS identified SNORD78, a small nucleolar RNA, as a previously unrecognized oncogenic mediator in colorectal cancer. The key mechanism centers on protein ubiquitination: SNORD78 competitively occupies the Lys221 ubiquitination site of IMP2 — an m6A (N6-methyladenosine) RNA reader protein — outcompeting the E3 ubiquitin ligase TRIM25. By blocking TRIM25-mediated ubiquitination at that specific lysine residue, SNORD78 prevents proteasomal degradation of IMP2, effectively prolonging its activity. Stabilized IMP2 then recognizes m6A modifications on the CHKA transcript (choline kinase alpha), amplifying phospholipid biosynthesis. This metabolic reprogramming appears to provide colorectal tumor cells with membrane-building material and signaling lipids that support sustained proliferation.
This work sits at the intersection of three rapidly evolving fields — epitranscriptomics, ubiquitin biology, and cancer metabolism — and the convergence is analytically significant. The m6A modification system has attracted intense interest since the identification of METTL3, YTHDF readers, and FTO erasers, but the role of IMP2 (also called IGF2BP2) as a stability-promoting m6A reader is less thoroughly characterized in colorectal contexts. What is notably novel here is the mechanism by which a snoRNA — classically viewed as a ribosome-modification factor — physically competes at a protein ubiquitination site, acting almost as a decoy ligand. This concept of RNA-protein competition at post-translational regulatory nodes is underexplored and may prove generalizable to other cancers. Limitations include the PNAS excerpt's brevity, which makes it impossible to assess cohort sizes, in vivo model depth, or whether pharmacological inhibition of this axis shows therapeutic efficacy. The study appears mechanistic rather than translational at this stage.